43 results
8-K
EX-1.1
LRMR
Larimar Therapeutics Inc
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
forth onAnnex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated June 27, 2018 and each “free-writing prospectus” (as defined … in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the applicable requirements of the Securities Act
8-K
EX-1.1
LRMR
Larimar Therapeutics Inc
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
that is first filed pursuant to Rule 424(b) under the Securities Act, together with the Base Prospectus.
The “Pricing Disclosure Package” shall mean (i) the Base … ”), that the parties hereto shall hereafter expressly agree in writing to treat as part of the Pricing Disclosure Package.
As used herein, “Applicable
8-K
EX-10.2
LRMR
Larimar Therapeutics Inc
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
from time to time.
7. Expenses.
The Company will provide a relocation package in 2018 whereby the Company will reimburse you up to a certain amount
8-K/A
EX-99.3
xaa1nnkmxfdvo
26 Jun 20
Other Events
5:08pm
PRE 14A
r6o4eeqg
12 Apr 24
Preliminary proxy
6:06am
424B5
a1hodo43mx93r7 p1f
9 Nov 18
Prospectus supplement for primary offering
4:49pm